A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak żołądka lub jego złączenia z przełykiem, rozprzestrzeniający się na inne części ciała lub niemożliwy do operacyjnego usunięcia
- •Możliwość przyjmowania leczenia ramucirumabem i paclitakselem
- •Nawrót choroby lub pogorszenie się stanu podczas lub po poprzednim leczeniu (stwierdzone obrazowaniem)
- •Widoczne zmiany nowotworowe, które można zmierzyć na badaniach tomograficznych
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (ECOG 0-1)
- •Spodziewana długość życia co najmniej 3 miesiące
- •Wiek co najmniej 18 lat (19 lat w Korei)
- •Prawidłowe funkcjonowanie organów wewnętrznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (27)
City of Hope
Duarte, United States
City of Hope at Orange County Lennar Foundation Cancer Center
Irvine, United States
University of California, Los Angeles
Santa Monica, United States
Texas Oncology Arlington North
Arlington, United States
Texas Oncology Bedford
Bedford, United States
Texas Oncology Dallas Methodist
Dallas, United States
Texas Oncology Dallas Medical City
Dallas, United States
Texas Oncology Dallas Presbyterian
Dallas, United States
Texas Oncology Methodist Charlton Cancer Center
Dallas, United States
Texas Oncology-Sammons Cancer Center
Dallas, United States
Texas Oncology Fort Worth Cancer Center
Fort Worth, United States
Texas Oncology Grapevine
Grapevine, United States
Texas Oncology Plano East
Plano, United States
Texas Oncology Plano West
Plano, United States
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
Yokohama, Japan
Saitama Prefectural Hospital Organization Saitama Cancer Center
Shinden, Japan
Shizuoka Cancer Center
Nagaizumi-cho, Japan
National Cancer Center Hospital
Chūōku, Japan
Osaka International Cancer Institute
Chūōku, Japan
National Cancer Center Hospital East
Kashiwa, Japan
The Cancer Institute Hospital of JFCR
Kōtoku, Japan
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Chonnam National University Hwasun Hospital
Hwasun, South Korea
Kyungpook National University Chilgok Hospital
Daegu, South Korea
Severance Hospital
Seoul, South Korea
ASAN Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Trial contact
(Asia sites)Toray Contact for Clinical Trial Information
(US sites) Contact for Clinical Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.